Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Olaratumab and Rechallenge With Doxorubicin in Anthracycline Pretreated, Advanced Soft Tissue Sarcoma Patients. An Exploratory Phase-II Study

NCT03698227 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT03698227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Olaratumab and Rechallenge With Doxorubicin in Anthracycline Pretreated, Advanced Soft Tissue Sarcoma Patients. An Exploratory Phase-II Study
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Terminated
Start date
November 12, 2018
Completion date
June 25, 2020
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft tissue sarcoma